Delivery Order SPE2DB25D2204-SPE2DB25FTGQQ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Belbuca 300 mcg film (60-count), with a ceiling value of $1,075.23. This is a firm fixed-price delivery order with an ultimate completion date of September 16, 2025. The award was made through open competition with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this...
- The Defense Logistics Agency awarded a $1,455.48 delivery order to AmerisourceBergen Drug Corp for BELBUCA 750 microgram film (60 count) on September 19, 2025, with completion targeted for September 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the pharmaceutical distributor's Conshohocken, Pennsylvania facility. The award represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with...
- The Defense Logistics Agency awarded a $1,301.11 delivery order to AmerisourceBergen Drug Corp for the supply of Belbuca 900 mcg film (60 count) under a firm fixed price contract. The order, issued on April 24, 2025, with an ultimate completion date of April 25, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement needs. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $1,168.12 delivery order to AmerisourceBergen Drug Corp for BELBUCA 750 MCG film (60 count) on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was competitively granted with no...
- The Defense Logistics Agency awarded a delivery order valued at $2,045.41 to AmerisourceBergen Drug Corp for 60 units of Belbuca 600 microgram film on November 5, 2025, with completion scheduled for November 6, 2025. This is a firm fixed-price, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $1,644.43 to AmerisourceBergen Drug Corp for Belbuca 300 mcg film (60 count) on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, which is not set aside, represents a pharmaceutical supply delivery under the company's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a...
- This is a $1,000.47 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of BELBUCA 900 MCG FILM 60S, a pharmaceutical product, to support military healthcare programs. The contract has an ultimate completion date of April 14, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- The Defense Logistics Agency awarded a $1,301.28 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for Belbuca 450 mcg film, with an ultimate completion date of September 19, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. Belbuca is a buccal film formulation used for pain management in opioid-tolerant patients. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,061.52 to AmerisourceBergen Drug Corp for BELBUCA 300 MCG Film (60 count) on July 25, 2025, with completion expected by July 28, 2025. This is a firm fixed price, non-set-aside contract executed as a child order under AmerisourceBergen's broader pharmaceutical supply agreements with DLA. The product is a buccal film formulation used for pain management, reflecting the company's role as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on October 17, 2025, for the supply of Belbuca 600 microgram films (60 count). This competitively awarded, non-set-aside delivery order carries a ceiling value of $2,683.50 with firm fixed pricing and an ultimate completion date of October 20, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB25D2204Indefinite Delivery Contract
- SPE2DB25D2204-SPE2DB25FTGQQDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order valued at $3,635.46 by the Defense Logistics Agency on June 13, 2025, with an ultimate completion date of June 16, 2025. The contract, which carries no set-aside designation, calls for the delivery of Belbuca 300 microgram film (60 count), a buccal film formulation used for pain management. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The Belbuca delivery represents a routine pharmaceutical supply replenishment through AmerisourceBergen's comprehensive global pharmaceutical support vehicle with the Defense Logistics Agency. As a prime vendor in the DLA Medical Supply Chain, AmerisourceBergen serves critical healthcare needs across military and veteran healthcare systems, delivering brand-name and generic medications, vaccines, and specialized medical supplies through competitively awarded contracts. This transaction exemplifies the company's role as a key supplier of pain management pharmaceuticals and other therapeutic medications supporting the Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 6/13/25 |